Abstract:In this study, we have investigated 6 novel influenza‐derived peptides predicted to be restricted to the understudied HLA‐B*18:01 molecule. We identified that 3/6 of the novel peptides were immunogenic in samples from several donors and restricted to HLA‐B*18:01 as predicted and were further characterised. Objectives Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza‐derived peptides from internal structural and non‐structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA‐I). Each HLA‐I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell‐mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules. Methods Here, we assessed the immunogenicity of six recently published novel influenza‐derived peptides identified by mass‐spectrometry and predicted to bind to the prevalent HLA‐B*18:01 molecule. Results Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA‐B*18:01+ individuals and confirmed their HLA‐B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA‐B*18:01‐restricted NP219 peptide. Using X‐ray crystallography, we solved the first crystal structures of HLA‐B*18:01 presenting immunogenic influenza‐derived peptides. Finally, we dissected the first TCR repertoires specific for HLA‐B*18:01 restricted pathogen‐derived peptides, identifying private and restricted repertoires against each of the four peptides. Conclusion Overall the characterisation of these novel immunogenic peptides provides additional HLA‐B*18:01‐restricted vaccine targets derived from the Matrix protein 1 and potentially the non‐structural protein and the RNA polymerase catalytic subunit of influenza viruses.

A targeted single mutation in influenza A virus universal epitope transforms immunogenicity and protective immunity via CD4+ T cell activation

Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance

The Immunodominant Influenza A Virus M158–66Cytotoxic T Lymphocyte Epitope Exhibits Degenerate Class I Major Histocompatibility Complex Restriction in Humans

Identification and relative abundance of naturally presented and cross-reactive influenza A virus MHC class I-restricted T cell epitopes

Immunogenic Stimulus for Germline Precursors of Antibodies That Engage the Influenza Hemagglutinin Receptor-Binding Site.

Age-dependent heterogeneity in the antigenic effects of mutations to influenza hemagglutinin

The Immunodominant Influenza A Virus M1(58-66) Cytotoxic T Lymphocyte Epitope Exhibits Degenerate Class I Major Histocompatibility Complex Restriction In Humans

CD8+ T-cell responses towards conserved influenza B virus epitopes across anatomical sites and age

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Applying Unique Molecular Identifiers in Next Generation Sequencing Reveals a Constrained Viral Quasispecies Evolution under Cross-Reactive Antibody Pressure Targeting Long Alpha Helix of Hemagglutinin

Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

Secondary Heterosubtypic Influenza Infections Result in Radically Different T Cell Immunodominance Hierarchies and Clinical Outcomes (VIR5P.1137)

A naturally protective epitope of limited variability as an influenza vaccine target

Vaccine-Induced Antibodies That Neutralize Group 1 and Group 2 Influenza A Viruses.

A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination

Single-Cell Approach to Influenza-Specific CD8+ T Cell Receptor Repertoires Across Different Age Groups, Tissues, and Following Influenza Virus Infection

Structural and immunological characterization of the H3 influenza hemagglutinin during antigenic drift

Sequential Immunizations with Heterosubtypic Virus-Like Particles Elicit Cross Protection Against Divergent Influenza A Viruses in Mice

Characterisation of novel influenza‐derived HLA‐B*18:01‐restricted epitopes

Sequential immunization with chimeric hemagglutinin ΔNS1 attenuated influenza vaccines induces broad humoral and cellular immunity

Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses.